Background: Type 2 diabetes is a global health concern, with an increased prevalence and high cost of treatment.
burden of $3.4 billion, which is estimated to increase to 41% by 2026 (3) . Diabetes contributes to 30% of stroke, 40% of heart attacks, 50% of kidney failure requiring dialysis, and 70% of nontraumatic lower limb amputations, and is a leading cause of blindness (4) . A quarter of Canadians with diabetes indicate that cost of treatment influences their adherence (5) . Low-cost treatments are needed to reduce morbidity, long-term medical costs, and mortality (6) .
Emerging evidence demonstrates that vitamin D supplementation may play a role in the prevention of type 2 diabetes. Vitamin D deficiency is involved in abnormal glucose metabolism, altered insulin secretion, and type 2 diabetes (7) (8) (9) (10) . Vitamin D deficiency is common in type 2 diabetes (11). Mitri et al. (12) (13) (14) .
Mechanistically, vitamin D provides protection from diabetes-related complications through its anti-inflammatory and immune-modulatory effects (15, 16) , as well as attenuating the expression of proinflammatory cytokines involved in insulin resistance like interleukin-1 and interleukin-6 (17) . At a cellular level, the active form of vitamin D, 1,25-dihydroxyvitamin D, regulates expression of the insulin receptor gene (18, 19) , facilitates glucose transport into muscle cells (20) , and suppresses renin gene expression following hyperglycemia by blocking renin-angiotensin activity (21, 22) . In addition, elevation of parathyroid hormone in response to vitamin D deficiency may also reduce insulin release from pancreatic b cells (23) .
Despite promising results in longitudinal observational studies, demonstrating the inverse association between serum 25(OH)D status and type 2 diabetes, results of clinical trials with vitamin D have been inconclusive. In the systematic reviews conducted by George et al. (24) , Pittas et al. (14) , and Mitri et al. (7) , there was an improvement in fasting plasma glucose (FPG) and insulin resistance, when they investigated the patients with diabetes or impaired glucose tolerance, rather than the healthy population. Still, the potential benefits of vitamin D supplementation on glycemic control and insulin sensitivity are debated by others (25) (26) (27) . The lack of appropriate evidence for the beneficial effects of vitamin D might be attributed to suboptimal dosing (28, 29) , short duration of supplementation (30, 31) , small sample size (28, 29, 32) , and comorbid conditions like obesity (33) . Obesity is associated with systemic low-grade inflammation leading to insulin resistance and metabolic disorders such as diabetes (34) . Several studies have reported that vitamin D improves insulin sensitivity and decreases inflammation (14, 35) . Obese individuals are more likely to be vitamin D deficient, and need two to three times higher doses of vitamin D supplementation for repletion (36) . Each unit (kg/m 2 ) increase in body mass index (BMI) is associated with a 1.15% decrease in serum 25(OH)D concentrations (37) . Current evidence is inconclusive, and it remains unclear whether vitamin D supplementation through clinical trials has a favorable effect on glycemic control in patients with type 2 diabetes. The objective of the current review was to resolve the uncertainty by systematically reviewing the literature and performing a meta-analysis of randomized controlled trials investigating the effects of vitamin D supplementation in type 2 diabetic patients on glycemic parameters, including FPG, homeostatic model assessment of insulin resistance (HOMA-IR), and glycosylated hemoglobin (HbA1c).
Materials and Methods

Literature search strategy
We designed this study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Guidelines (38, 39) . The protocol for our systematic review was registered with the International Prospective Register of Systematic Reviews, PROSPERO (registration CRD42017059555 Search terms included "type 2 diabetes mellitus" (or "HbA1c" or "hyperglycemia" or "insulin resistant" or "glucose'') and "vitamin D" (or "vitamin D3" or "cholecalciferol" or "25 hydroxyvitamin D" or "vitamin D deficiency") in the title or abstract. The reference lists of the retrieved articles were scanned for additional eligible studies. An e-mail was sent to the correspondence author for additional data when relevant. Two authors (N.M. and M.M.) performed the initial screening of titles and abstracts.
Selection criteria
We reviewed all randomized control trials (RCTs) evaluating the effect of vitamin D administration on glycemic measures.
Eligible studies met the following criteria: (1) Study was placebo controlled; (2) study population was patients with type 2 diabetes; (3) participants were $18 years; (4) interventions were vitamin D supplementation with/without calcium supplementation vs placebo; (5) vitamin D supplementation dose was daily or weekly; (6) trial length was $2 months; (7) serum 25(OH)D levels and at least one of the glycemic measures (HbA1c, FPG, HOMA-IR) were reported at the beginning and at the end of the trial for both treated and control groups; and (8) study was published in English. Exclusion criteria were as follows: (1) nonclinical studies, observational studies, case-control or crosssectional studies; (2) studies with insufficient information on outcomes, after the corresponding author was contacted; (3) narrative reviews, comments, opinion pieces, methodological reports, editorials, and letters; (4) study populations of healthy individuals, gestational diabetics, individuals with diabetic nephropathy, type 1 diabetics, and prediabetics; (5) intervention periods of ,2 months; (6) vitamin D supplementation provided as a monthly or a single bolus dose; and (7) study performed in children (,18 years). Following the screening of titles and abstracts, duplicates were removed by two authors (N.M. and M.M.). Study selection, based on meeting the inclusion criteria, was approved by another author (S.M.K.). Any disagreements between the authors were resolved through discussion with the fourth author (H.V.) (Fig. 1) .
Data extraction and management
Data were extracted by two authors (N.M., M.M.). Following assessment of methodological quality of the trials by the first and second reviewers (N.M. and M.M.), extracted data were approved by the other reviewers (S.M.K. and H.V.). Data extracted from each study included the following items: first author, reference, year of publication, country of study, study design, inclusion criteria, sample size, form of vitamin D, dose and frequency of vitamin D supplementation, method used for serum 25(OH)D measurement, any cosupplementation, calcium dose (if coadministered), control group, duration of supplementation, participants' characteristics [sex (n, % male), age, weight, BMI], comorbidities, baseline, and follow-up serum 25(OH)D levels and outcome measures (HbA1c, FPG, HOMA-IR).
Any further necessary calculation on study data, such as converting measuring units or calculating standard deviation (SD), was conducted by the first author (N.M.) and checked by another author (M.M.). Serum 25(OH)D levels were collated in nmol/L; a multiplication factor of 2.5 was used to convert 25(OH)D levels respectively from ng/mL to nmol/L (40) . Plasma glucose levels were collated in mmol/L; we used a multiplication factor of 0.0555 to convert glucose levels respectively from mg/dL to mmol/L, as appropriate (41) .
Quality assessment
The quality of selected RCTs was assessed by two authors (N.M., M.M.) using a checklist from the Cochrane Collaboration (42) . The major criteria of the checklist were randomization, double blind (both patients and researcher/assessor), comparability of treatment groups, available follow-up information, if intent-to-treat analysis applied, and equal treatment used for treatment groups. The detailed checklist has been presented in the Cochrane Collaboration (42) . Each criterion might be answered in three ways: yes (adequate information), no (inadequate information), or unclear information. Criteria answered with (1) yes, scored one point; (2) no, scored zero points; or (3) unclear information, scored as U and zero points. A total score was summed for each study. A study was considered good quality with a total score $9 points.
Data synthesis and statistical analysis
For each study, the effect size was calculated using the mean change from baseline in glycemic measures and SD for both treatment and control groups (42) . The net change in each measurement was calculated by subtracting the mean measure at baseline from the mean measure at the end of the follow-up (43) . SD was calculated using the standard error (SE) of the mean via the following formula: SD = SE of the mean 3 square root (n), where n is the number of the subjects (43) . When SD of mean change for an outcome measure was not reported, we derived SD of mean change as the mean of the baseline and follow-up SDs for each group (24) . If a study included more than two intervention groups, the highest dose of vitamin D supplementation was selected and its data presented in comparison with the placebo (control) group. If studies compared both vitamin D and/or calcium supplementation vs placebo, they were treated as multiple studies (i.e., vitamin D vs placebo and vitamin D plus calcium vs placebo).
Analyses were performed using Comprehensive MetaAnalysis V3 software (Biostat 2014, Englewood, NJ) (44) . Random-effects models (DerSimonian-Laird method) were used to estimate expected heterogeneity of outcomes (45) . Heterogeneity was assessed using I 2 index with I 2 values $50% corresponded to the use of random-effects model, and the values .60% to 70% indicated substantial heterogeneity (46) . The effect size was reported using standardized mean difference with a 95% confidence interval (CI). Significance was considered a P value ,0.05. A sensitivity analysis was performed using the leave-one-out method (removing one study each time and repeating the analysis) (47) . To address the impact of unique populations, we removed the nine clinical trials conducted in Iran and repeated the meta-analysis.
Publication bias
Potential publication bias was assessed using a visual inspection of Begg funnel plot asymmetry and Egger weighted regression tests (48) . The Duval and Tweedie trim-and-fill method was used to adjust the analysis for the effects of publication bias (49) .
Subgroup analysis
To address heterogeneity among study populations, subgroup analyses were performed as follows: coadministration of calcium vs vitamin D supplementation alone; vitamin D insufficiency vs sufficiency (50) 
Results
Summary of searches and study selection process
A total of 844 unique citations was identified through searches, of which 256 records remained after removal of duplicates. After screening via titles and abstracts, 108 articles remained for further evaluation. Following further evaluation, 84 more articles were excluded for the following reasons: study design was not RCT (n = 13), conducted in healthy population or prediabetics (n = 28), duration of follow-up was too short (,2 months) (n = 6), monthly or single bolus dose of vitamin D supplementation (n = 6), studies conducted in children or pregnant women (n = 19), insufficient information of vitamin D status at the beginning of the intervention and/or at the end of the trial (n = 12). For three studies, an e-mail request for additional data was sent to corresponding author of each study, but with no response these studies were removed from further analysis. Therefore, a total of 24 clinical trials including 1528 participants with type 2 diabetes was included in the current meta-analysis (Fig. 1) .
Characteristics of the included studies
Detailed information of the included studies is summarized in Table 1 (12, (28) (29) (30) (31) (32) (33) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) . There were 24 studies published between 2009 and 2016 that met the inclusion criteria from different countries, including United States of America (n = 1), East Asia (n = 2), South East Asia (n = 1), South West Asia (n = 1), Australia and New Zealand (n = 2), Iran (n = 9), other Middle East countries (n = 3), Israel (n = 1), Europe (n = 3), and Nigeria (n = 1). All were randomized placebo-controlled trials, including three studies that compared vitamin Dfortified yogurt with plain yogurt (placebo) (52, 56, 65) . 29). With the exception of two studies that included only women participants (12, 65) , all studies included both men and women. Mean age varied from 40 to 67 years (28, 61) . At the beginning of the trial, mean serum 25(OH)D levels varied from 7 ng/mL (17 nmol/L) (55) to 34 ng/mL (84 nmol/L) (51) in the intervention group. Serum 25(OH)D concentration was measured using radioimmunoassay (n = 6) (12, 32, 33, 57, 59), high-performance liquid chromatography (n = 4) (51, 52, 55), chemiluminescence immunoassay (n = 5) (54, 60, 62, 64), liquid chromatography mass spectrometry (n = 1) (53), and enzyme-linked immunosorbent assay (n = 6) (29-31, 51, 63, 65) , and the method was not reported for two studies (28, 61) .
Eleven studies included only type 2 diabetic patients who were vitamin D insufficient based on the Institute of Medicine [serum 25(OH)D ,20 ng/mL (,50 nmol/L)] (51) at the beginning of the trial (12, 29, 31, 53, 55, 57, 58, (60) (61) (62) (63) . Five studies included overweight and obese (BMI $25 kg/m 2 ) diabetic patients (28, 33, 54, 59, 60) . A range of vitamin D doses, from 10 mg/d (400 IU/d) to 212 mg/d (8500 IU/d), was administered in these trials (61, 64) . Six studies included weekly doses of vitamin D rather than daily supplementation (32, 33, 51, 57, 61, 63) . Calcium was coadministered with vitamin D in five studies (33, 52, 56, 58, 61) . Duration of vitamin D supplementation ranged from 2 months to 12 months (28, 33, 54, 57) . As the main exposure of interest, we looked into serum 25(OH)D concentration following vitamin D supplementation. The mean change in serum 25(OH)D levels between the intervention and control groups is summarized for each study in Supplemental Fig. 2 ). Body weight information was available for five studies (52, 56, 60, 64, 65) . Vitamin D-supplemented individuals did not show any significant change in body weight, relative to individuals in the placebo groups (20.51 kg; 95% CI: 21.32 to 0.30, P = 0.2).
Risk of bias assessment
All included studies had a low risk of bias according to randomization, allocation concealment, and comparability of intervention groups at the beginning of the trial and equal treatment of intervention groups. However, there was a lack of information about intention-to-treat analysis. The quality assessment of the included trials resulted in 17 of 22 studies showing good quality, with the Cochrane score $9 (28, 30, 31, 33, 51-54, 56-60, 62-65) (Supplemental Table 1 ).
Pooled estimate of the effect of vitamin D on glycemic measures
Effect on HbA1c
There were 23 studies with sufficient data to be included in the meta-analysis to measure the overall effect of vitamin D supplementation and improved serum 25(OH)D status on HbA1c (28) (29) (30) (31) (32) (33) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) . The total number of included diabetic patients was 1477; of these, 746 received vitamin D supplementation with or without calcium, and 731 patients received placebo. Ten of 23 studies reported a significant reduction in HbA1c after vitamin D supplementation compared with placebo (51, 54, 55-57, 59, 61, 64, 65) . Three additional studies showed a decreasing trend in the mean change of HbA1c in the vitamin D group compared with the placebo group; however, these differences were not statistically significant (52, 53, 60) .
Based on a random-effect meta-analysis, comparing the mean change in HbA1c from baseline between vitamin D-supplemented and placebo groups, the overall effect was a significant reduction in HbA1c after vitamin D supplementation (standardized difference in mean: 20.30%; 95% CI: 20.45 to 20.15, P , 0.001) (Fig. 2) .
In three studies, coadministration of vitamin D with calcium led to a significant decrease in HbA1c in the treated group vs placebo group (56, 57, 61) . There was a significantly greater reduction in the mean change of Table 2) . Risk of bias assessment based on inclusion of the studies that were characterized as good quality, based on Cochrane score $9, did not change the overall result (mean change: 20.31; 95% CI: 20.47 to 20.15, P , 0.001). Heterogeneity was present (I 2 = 96%), and visual inspection of funnel plot symmetry did suggest potential publication bias [ Fig. 3(a) ], which was confirmed by Egger's linear regression (intercept = 22.6; SE = 1.03; 95% CI: 24.75 to 20.43, t = 22.5, P = 0.02). We adjusted the effect size for potential publication bias using the trim and fill correction (with no potentially missing study to be imputed in the funnel plot) and found an overall reduction in HbA1c with vitamin D supplementation (with or without calcium) of 0.30% [95% CI: 20.45 to 20.15, P , 0.001; Fig. 3(b) ].
Effect on FPG
There were 21 studies that reported FPG as an outcome measure (12, 28-33, 52-61, 63, 65) . Six studies reported a significant reduction in FPG (52, 54, 56, 61, 63, 65) , whereas three studies demonstrated a decreasing trend in FPG after vitamin D supplementation (55, 59, 60) .
A pooled meta-analysis including 1386 patients with type 2 diabetes (n = 701 treated with vitamin D and n = 685 with placebo) was performed to compare the mean change in FPG between the beginning and the end of study. Vitamin D supplementation resulted in a significant reduction of FPG with a standardized mean difference of 24. No evidence of publication bias was detected using funnel plot [Supplemental Fig. 4 
Effect on insulin resistance (HOMA-IR)
Twelve studies provided sufficient data to measure the overall effect of vitamin D supplementation on insulin resistance using HOMA-IR (12, 32, 33, 53, 54, (56) (57) (58) (59) 65) . The total number of included diabetic patients was 757, of whom 386 were included in the vitamin D group and 371 in the placebo group. Seven of the 12 studies observed a significant reduction in insulin resistance after vitamin D intervention compared with placebo (12, 33, 54, 56, 57, 65) and five did not.
We found a significant lowering effect of vitamin D supplementation on insulin resistance compared with controls (standardized difference in means: 20.66; 95% CI: 21.06 to 20.26, P = 0.001; Supplemental Fig. 5) .
Asymmetry of funnel plot was suggestive of potential publication bias [Supplemental Fig. 6(a) ], but Egger's test did not find a publication bias (intercept = 21.76; SE = 2.6; 95% CI: 27.5 to 3.98, t = 20.68, P = 0.51). To evaluate potential publication bias, the effect size was adjusted using the trim and fill correction, and one missing study was imputed in the funnel plot [Supplemental Fig. 6(b) ]. The adjusted mean difference was 20.72 (95% CI: 21.11 to 20.33, P , 0.001).
Calcium was coadministered with vitamin D in four studies (33, (56) (57) (58) with no significant effect on HOMA-IR changes (Table 2) 
Sensitivity analysis
Using the leave-one-out method, the pooled effect of vitamin D supplementation on HbA1c, FPG, and HOMA-IR remained similar across all included studies. This confirmed that the significant effect of vitamin D supplementation on glycemic measures was the overall effect of all included studies.
After removing the nine trials conducted in Iran, HbA1c (20.105%; 95% CI: 20.27 to 0.06, P = 0.2), FPG (21.6 mg/dL; 95% CI: 24.47 to 1.35, P = 0.2), and HOMA-IR (20.09; 95% CI: 20.41 to 0.23, P = 0.4) were not significantly reduced following vitamin D supplementation compared with the placebo. Removing these studies decreased the power such that 69.5%, 67.0%, and 52.8% of the population remained for HbA1c, FPG, and insulin, respectively. However, glycemic parameter changes were in the same direction with vitamin D supplementation.
Discussion
We conducted a systematic review and meta-analysis of 24 RCTs to determine the efficacy of vitamin D supplementation on glycemic control and insulin sensitivity in diabetic patients. This unique meta-analysis was comprised of well-designed clinical trials centered on diabetic patients from diverse countries with high prevalence of vitamin D deficiency and poorly controlled type 2 diabetes. Extended follow-up periods (average of 7 months) and high daily doses (average of 4200 IU/d) increased the chances of achieving physiologically favorable levels of serum 25(OH)D (100 to 130 nmol/L), which is essential for better glycemic controls. Our meta-analysis found that vitamin D supplementation and subsequent increased serum 25 (OH)D levels improved glucose control and insulin resistance in type 2 diabetic patients. Significant reductions in HbA1c, FPG, and HOMA-IR were found with vitamin D supplementation.
Overall, vitamin D supplementation seems to be efficacious as an adjuvant treatment of diabetes-related glucose metabolism disorders. The results of the current meta-analysis suggest that a minimum dose of 100 mg/d (4000 IU/d), which is equivalent to the tolerable upper intake level of vitamin D for adults (66) , is required to have a protective effect on glucose homeostasis in type 2 diabetic patients.
Vitamin D deficiency, like other nutritional deficiencies, may compromise different body functions like glucose homeostasis (67) . A majority of diabetic patients have been found to be vitamin D insufficient (68) . Observational studies demonstrate an inverse association between serum 25(OH)D levels and the incidence of type 2 diabetes (69). In agreement with our findings, other studies have reported that vitamin D supplementation improves glycemic control and insulin sensitivity (7, 14, 54, 61, 65) .
However, as may be expected with varied study designs (such as dose, duration, population characteristics, concomitant medications, etc.), results from numerous other RCTs have conflicted. A recent metaanalysis by Krul-Poel et al. (70) , for instance, did not recover any beneficial effect of short-term vitamin D supplementation in a diverse population with type 2 diabetes. Yet, it is notable that these authors principally included trials that used single or monthly vitamin D supplementation, despite evidence that the two are not equivalent and daily doses are recommended (71) . KrulPoel et al. (70) also included clinical trials with relatively short follow-up periods, often ,3 months. This is particularly problematic because HbA1c has a life span of ;100 days (72), meaning that any change induced would take longer to detect. In our meta-analysis, studies shorter than 2 months in duration were excluded to account for biology, and the average of followup periods was 7 months. As a result of the study inclusion criteria, the average vitamin D supplementation dose in the study by Krul-Poel et al. (70) was lower than that used in the present meta-analysis (3600 IU/d compared with 4200 IU/d), and the average increase in serum 25(OH) levels was less (12 ng/mL compared with 17 ng/mL).
Krul-Poel et al. (70) did, however, find beneficial effect of vitamin D in diabetic patients with poor glycemic control. Previous works had noted that in compromised conditions (high and poorly controlled HbA1c), vitamin D supplementation might improve glycemic measures even with lower doses and shorter period of supplementation (70, 72) . The results of our meta-analysis further corroborate these findings.
Our systematic review showed that baseline vitamin D insufficiency had a negative influence on glycemic measure outcomes such that positive outcomes were found with higher baseline 25(OH)D levels ( Table 2 ). The authors posit that optimal glucose homeostasis is enabled by a physiological vitamin D status achieved through targeted supplementation and/or regular sun exposure containing UVB, a level that may be reflected by serum 25(OH)D concentrations .40 ng/mL (100 nmol/L) (73) . In the current study, we found that 100 mg/d (4000 IU/d) vitamin D was required for efficacy.
There is evidence that body weight loss improves some biomarker concentrations, including cholesterol, glucose, and insulin (74) . As such, the positive results observed in single vitamin D supplementation trials could be seen as a consequence of energy restriction and weight loss; the lack of appropriate response in obese individual might also be related to weight control failure (75) . However, a closer examination of the trials included in our metaanalysis revealed that there were no significant weight reductions that could have boosted glycemic control. In addition, the diet and medications of the supplemented and placebo groups in the included trials were comparable, and even a slight decrease in BMI over time might be attributed to improved serum 25(OH)D levels in vitamin D-supplemented group. Significant reductions in FPG and HOMA-IR were also recorded in obese individuals; therefore, the lack of a response in obese diabetic patients might be related to lack of vitamin D repletion [serum 25(OH)D levels $75 nmol/L] rather than controlling weight (25, 76) . von Hurst et al. (12) similarly showed significant improvement in insulin resistance among insulin-resistant women, despite there being no effect on body weight or C-reactive protein level after 6 months of 4000 IU/d vitamin D supplementation. Overall, improved serum 25(OH)D levels have shown promising results for glycemic control, although other parameters such as age, season, ethnicity, obesity, and physical activity level should be taken into consideration.
We found that reductions in HbA1c, FPG, and HOMA-IR were all significantly greater in nonobese patients (Table 2 ). This may be due to the influence of body mass (fat mass) on the required vitamin D dose to achieve the same serum 25 (36) . To obtain physiological levels, obese individuals require doses in excess of 150 mg/day (two to three times as much vitamin D as normal weight individuals). It is postulated that higher doses of vitamin D may be required to compensate for vitamin D trapped in fat mass and/or inadequate vitamin D status (73, 78, 79) .
The recommended vitamin D supplementation dose suggested by this meta-analysis [100 mg/d (4000 IU/d)] is likely to result in serum 25(OH)D levels of .40 ng/mL (100 nmol/L) in normal weight and possibly overweight patients; however, these doses should be adjusted in obese diabetic patients (78) . The overall increase in 25(OH)D was substantial at 17 ng/mL (42 nmol/L) (Supplemental Fig. 1 ). If we consider that nonobese subjects, who experience greater increases in 25(OH)D and higher baseline 25(OH)D concentrations, had improved glycemic control, and the adequate vitamin D dose was found to be .100 mg/d (4000 IU/d), one may conclude that studies with inconclusive results simply fail to reach the physiological vitamin D status. In support, if we look at the population characteristics of the trials that reported HbA1c (n = 23), the negative trials included participants who were vitamin D insufficient and/or obese (12, 28-33, 52, 53, 58, 60, 62, 63) .
The studies included in this meta-analysis were not totally heterogeneous (high I 2 ) and used radioimmunoassay, highperformance liquid chromatography, chemiluminescence immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry-methods that are not fully harmonized. Coefficients of variation ranged between 11% and 25% (80) , which may over-or underestimate serum 25(OH)D levels (81) . The physiological 25(OH)D concentration may vary based on the method of measurement. A combined analysis of individual level data from the studies analyzed in this work may elucidate an optimal serum 25(OH)D level for glycemic homeostasis as it would allow the use of standardized 25(OH)D concentrations and to take into account body weight. Overall, type 2 diabetic patients need more vitamin D than what is recommended for general population recommended daily allowance, for better glycemic control.
The prevalence of vitamin D deficiency is high in both developed (42% in United States, 32% in Canada, 40% in Europe) and developing countries (60% in Iran, 85% in India, 79% in Saudi Arabia) (82) (83) (84) (85) (86) , although substantially higher in developing countries. Baz-Hecht and Goldfine (87) have shown that the vitamin D supplementation improves glucose control and benefits insulin resistance in different vitamin D-deficient populations. Yet, the benefits of vitamin D supplementation and improved serum 25(OH)D levels on glycemic control are better highlighted in developing countries. In the current meta-analysis, we found improved glycemic control in different populations, including Iran, Norway, Australia, India, and Nigeria, suggesting that the effects of vitamin D are not unique to specific populations.
Vitamin D was found to improve insulin response and glycemic control. Pancreatic b cell impairment is crucial for the development and progression of type 2 diabetes (88) . Vitamin D plays an important role in the regulation of cellular calcium signaling with an indirect effect on regulating insulin secretion from pancreatic b cells (14, 89, 90) . Vitamin D may influence C-peptide secretion, an indicator of insulin secretion (91, 92) , and suppress reninangiotensin activity to preserve b cell function (93) . We found that coadministration of calcium with vitamin D improved the impact on glycemic measures, which may be due to the fact that calcium increases insulin sensitivity and improves glucose homeostasis (94, 95) . Moreover, vitamin D may improve glucose metabolism systemically through its anti-inflammatory and immunomodulatory effects (96) .
The standard of care for diabetes, established by the American Diabetes Association, recommends intensive lifestyle intervention and metformin for diabetes prevention (97) . Because of insufficient evidence, vitamin D supplementation in diabetic patients was not recommended to improve glycemic control (98) . We compared the changes from baseline of HOMA-IR, FPG, and HbA1c between vitamin D (current meta-analysis) and metformin from the study by Haffner et al. (99) to evaluate the clinical significance of vitamin D impact on glycemic control. The average intervention period was 6 to 7 months for vitamin D and 1 year for metformin; however, the lowering effect of vitamin D was half of that of metformin for HOMA-IR (20.66 vs 21.46), similar to that of metformin for FPG (20.27 mmo/L vs 20.27 mmol/L) and one-third of metformin for HbA1c (20.3% vs 21%). However, we believe that vitamin D is not a medication, but, based on our findings, should be included as an adjunct option to help improve glycemic control and provide an assortment of other health benefits.
Although these changes are somewhat modest, considering the differences in study design, sample size, and doses of vitamin D among individual clinical trials, the statistical significance of the pooled data demonstrates its clinical importance. Furthermore, in nutritional epidemiology, not all factors can be controlled for to mimic the real-life situation, and high effect sizes are not expected; rather, more consistent significance is preferred (100) . Hence, the current meta-analysis provides promising results for vitamin D as an adjuvant therapy for type 2 diabetes prevention and treatment.
There are several strengths of the current study. Higher numbers of studies included in this analysis, high-dose supplementation in more than half of the included studies, and longer period of trials have added to the value of this meta-analysis, compared with previous published ones. This review is based on an up-to-date literature search representing the most available data on this topic. All included studies were placebo-controlled randomized trials with acceptable methodological quality and the least probable chance of bias. Strength is added by including three different glycemic outcomes measures: HbA1c, FPG, and HOMA-IR. The majority of included studies had been designed for glycemic outcomes and included studies covering a diverse population. Furthermore, we relied on duplicate independent judgment in which two different reviewers independently performed the systematic review process. However, limitations exist in that the trials included in this review were heterogeneous according to the type of outcomes measured, vitamin D dosage, duration of supplementation, and comorbid conditions. A few studies were underpowered (16 to 30 participants per intervention group). We used random model in meta-analysis to overcome these limitations. Most of the included studies did not describe dietary intake and sun exposure contributing to vitamin D synthesis. It was, therefore, difficult to interpret results based solely on vitamin D supplementation. However, we accounted for this by including only studies that measured serum 25(OH)D at baseline and follow-up were included. There were a small number of studies that used calcium in parallel with vitamin D that were included in the meta-analysis for which subgroup analyses were conducted, but statistical significance may be affected by the number of included studies.
Conclusion
This systematic review showed that vitamin D supplementation can improve glycemic control, through lowering HbA1c, FPG, and HOMA-IR. A minimum dose of 100 mg/d (4000 IU/d), which brings serum 25(OH)D values to .40 ng/mL (100 nmol/L), is recommended to improve glycemic measures in type 2 diabetic patients. It seems that the effect of vitamin D was exerted mainly through promoting insulin sensitivity, with the major impact of supplementation on the reduction of HOMA-IR. Our study suggests that vitamin D supplementation could be recommended as adjunct therapy for patients suffering from type 2 diabetes. Clinical trials that examine the effects of vitamin D supplementation with coadministration of diabetic medications should be considered for future investigation to give an unequivocal response to whether vitamin D supplementation can improve glycemic measures in type 2 diabetic patients. Disclosure Summary: The authors have nothing to disclose.
